Researchers reported in Cell Death Discovery that blocking PHGDH can overcome dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma. The work centers on phosphoglycerate dehydrogenase (PHGDH), an enzyme involved in cellular metabolic pathways that have increasingly been targeted in oncology. The authors describe how inhibiting PHGDH alters metabolic dependencies associated with resistant tumors and restores sensitivity to dabrafenib. The findings position PHGDH as a potential combination target for patients who develop resistance to BRAF-directed therapy in a particularly aggressive thyroid cancer subtype. Clinically, the report suggests the value of pairing targeted agents with metabolism-focused interventions to counteract adaptive survival programs.